You are here: Home: Meet The Professors - Breast Cancer 1 | 2009: Case 2: Select Publications

Select Publications

Burstein HJ et al. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: Phase 2 results in patients with advanced HER2+ breast cancer. San Antonio Breast Cancer Symposium 2008;Abstract 37.

Buzdar AU et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13(1):228-33. Abstract

Gianni L et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: Primary efficacy analysis of the NOAH trial. San Antonio Breast Cancer Symposium 2008;Abstract 31.

O’Shaughnessy J et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc ASCO 2008;Abstract 1015.

Von Minckwitz G et al. Capecitabine vs capecitabine + trastuzumab in patients with HER2- positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). Proc ASCO 2008;Abstract 1025.